ClinicalTrials.gg
CompletedNCT01416116LIFTUpdated Apr 23, 2018

Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch

A Phase 4 interventional study of QUTENZA and Lidocaine in or Peripheral Nerve Injury (PNI) and Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN), sponsored by Astellas Pharma Inc. Completed at 20 sites in 7 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-04-23.

Sponsored by Astellas Pharma Inc · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The Summary of product characteristics (SmPC) for QUTENZA advises that topical anaesthetic is applied prior to the application of QUTENZA. This is a multi-center, randomized, assessor-blinded study which will investigate the use of an oral analgesic as an alternative form of pre-treatment for QUTENZA.

Read the detailed description

All patients will be treated with QUTENZA for 60 minutes. Patients will be randomized to one of two arms- application of topical anaesthetic (lidocaine cream) or an oral analgesic (tramadol oral tables) prior to application of QUTENZA. Patients will be followed up for 7 days to monitor pain scores and tolerability.

02

Conditions studied

  • or Peripheral Nerve Injury (PNI)
  • Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN)

Keywords

  • Tramadol
  • QUTENZA
  • Pre-treatment
  • Tolerability
03

In context

Peripheral Nerve Injuries

90 studies on the registry are indexed under Peripheral Nerve Injuries; 24 are open to participants now.

This study's enrollment of 122 is above the median of 46 across 62 interventional studies indexed under Peripheral Nerve Injuries.

Browse Peripheral Nerve Injuries studies →

Lead sponsor

Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of postherpetic neuralgia or neuropathic pain due to peripheral nerve injury
  • Daily pain score ≥ 4 for average pain both at the Screening Visit and at the Treatment Visit
  • Intact, non-irritated, dry skin over the painful area(s) to be treated

Exclusion criteria

Exclusion Criteria:

  • Significant ongoing or recurrent pain other than due to PHN or peripheral nerve injury
  • Past or current history of Type I or Type II diabetes mellitus
  • Active or treatment for malignancy within a year prior to the Treatment Visit
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Tramadol

    Tramadol prior to QUTENZA

    Drug: QUTENZA · Drug: Tramadol

  • Experimental
    Lidocaine

    Lidocaine prior to QUTENZA

    Drug: QUTENZA · Drug: Lidocaine

Interventions

06

What researchers measure

Primary outcomes

  1. The proportion of subjects who tolerate QUTENZA treatment

    A QUTENZA tolerant subject is defined as a subject receiving at least 90% of the intended patch duration.

    Time frame: 60 minute application period

Secondary outcomes

  1. Duration of patch application

    Time frame: 60 minutes

  2. Change in pain scores from baseline to subsequent timepoints on the day of patch application

    Time frame: 5, 25, 55, 85, 115 minutes on day of application and once a day on days 1, 2, 3

  3. Proportion of subjects using pain medications and dose of pain medication(s) administered

    Time frame: day 1-5

  4. Subject rated tolerability score

    Time frame: Baseline to end of study visit, day 7

07

Study locations

20 sites
  • Site 102
    Antwerpen, Belgium
  • Site 103
    Genk, Belgium
  • Site 101
    Roeselare, Belgium
  • Site 202
    Hradec Králové, Czechia
  • Site 203
    Olomouc, Czechia
  • Site 201
    Prague, Czechia
  • Site 302
    Aalborg, Denmark
  • Site 301
    Aarhus, Denmark
  • Site 402
    Cork, Ireland
  • Site 403
    Galway, Ireland
  • Site 404
    Galway, Ireland
  • Site 401
    Limerick, Ireland
  • Site 502
    Hamar, Norway
  • Site 501
    Skien, Norway
  • Site 603
    Kosice, Slovakia
  • Site 602
    Martin, Slovakia
  • Site 702
    Glasgow, United Kingdom
  • Site 701
    Liverpool, United Kingdom
  • Site 704
    Manchester, United Kingdom
  • Site 703
    Solihull, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2011 to primary completion in Apr 2012, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2011
First posted
Aug 12, 2011
StartActual
Jul 6, 2011
Primary completionActual
Apr 25, 2012
CompletionActual
Apr 25, 2012
Last update
Apr 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01416116
Responsible party
Sponsor
First posted
Aug 12, 2011
Start date
Jul 6, 2011
Primary completion
Apr 25, 2012
Completion
Apr 25, 2012
Last update
Apr 23, 2018

Study contacts

Senior Study Manager, Late Phase Clinical Development & Operations
study director · Astellas Pharma Europe Limited

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lidocaine · Tramadol

Start the discussion